Anavex Life Sciences Corp (AVXL)

[nidan7500]

Joseph K

Multiple vouchers for same rare pediatric disease. On this list, numbers 7, 9, 21, 24, and 29 are all priority review vouchers for drugs treating Duchenne muscular dystrophy; and 18 and 20 are both for Cystic fibrosis.
"Priority Review Vouchers for rare pediatric diseases, issued and sold 2012-present"
https://www.kidsvcancer.org/priority-review-vouchers/
Two questions seem relevant to some extent..
- may a rare pediatric disease voucher be issued for a disease that already has an approved treatment?

- has the same disease ever received
two pediatric rare disease vouchers?

So, the question presents itself then. "Is the FDA capable of chewing Gum AND Walking???